However, the combination of TMZ and RAD001, a PI3K-AKT-mTOR inhibitor, failed in patients with metastatic melanoma in a phase II clinical trial, which might indicate other resistance mechanisms [59]. The gene discussed is AKT1; the disease is metastatic melanoma.